ResearcherSt. Josef-HospitalActive in the last 2 years
Britta Majchrzak‐Stiller
Matched on ORCID iD 0000-0002-2169-9880; OpenAlex author ID A5002949414. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 9
2023: 1 paper · 2024: 2 papers
Papers 3
- Maintenance Therapy for Pancreatic Cancer, a New Approach Based on the Synergy between the Novel Agent GP-2250 (Misetionamide) and Gemcitabine. First author DOI 10.3390/cancers16142612↗
- Differential miRNA and Protein Expression Reveals miR-1285, Its Targets TGM2 and CDH-1, as Well as CD166 and S100A13 as Potential New Biomarkers in Patients wi… First author DOI 10.3390/cancers16152726↗
- GP-2250, a novel anticancer agent, inhibits the energy metabolism, activates AMP-Kinase and impairs the NF-kB pathway in pancreatic cancer cells. Co-author DOI 10.1111/jcmm.17825↗
Closest collaborators
The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Marie Buchholz · 3 shared papers, 2023–2024 · strength 0.55
- Paper Maintenance Therapy for Pancreatic Cancer, a New Approach Based on the Synergy between the Novel Agent GP-2250 (Misetio… DOI 10.3390/cancers16142612↗
- Paper GP-2250, a novel anticancer agent, inhibits the energy metabolism, activates AMP-Kinase and impairs the NF-kB pathway i… DOI 10.1111/jcmm.17825↗
- Paper Differential miRNA and Protein Expression Reveals miR-1285, Its Targets TGM2 and CDH-1, as Well as CD166 and S100A13 as… DOI 10.3390/cancers16152726↗
- Waldemar H. Uhl · 3 shared papers, 2023–2024 · strength 0.55
- Paper Maintenance Therapy for Pancreatic Cancer, a New Approach Based on the Synergy between the Novel Agent GP-2250 (Misetio… DOI 10.3390/cancers16142612↗
- Paper GP-2250, a novel anticancer agent, inhibits the energy metabolism, activates AMP-Kinase and impairs the NF-kB pathway i… DOI 10.1111/jcmm.17825↗
- Paper Differential miRNA and Protein Expression Reveals miR-1285, Its Targets TGM2 and CDH-1, as Well as CD166 and S100A13 as… DOI 10.3390/cancers16152726↗
- Chris Braumann · 3 shared papers, 2023–2024 · strength 0.55
- Paper Maintenance Therapy for Pancreatic Cancer, a New Approach Based on the Synergy between the Novel Agent GP-2250 (Misetio… DOI 10.3390/cancers16142612↗
- Paper GP-2250, a novel anticancer agent, inhibits the energy metabolism, activates AMP-Kinase and impairs the NF-kB pathway i… DOI 10.1111/jcmm.17825↗
- Paper Differential miRNA and Protein Expression Reveals miR-1285, Its Targets TGM2 and CDH-1, as Well as CD166 and S100A13 as… DOI 10.3390/cancers16152726↗
- Philipp Höhn · 3 shared papers, 2023–2024 · strength 0.55
- Paper Maintenance Therapy for Pancreatic Cancer, a New Approach Based on the Synergy between the Novel Agent GP-2250 (Misetio… DOI 10.3390/cancers16142612↗
- Paper GP-2250, a novel anticancer agent, inhibits the energy metabolism, activates AMP-Kinase and impairs the NF-kB pathway i… DOI 10.1111/jcmm.17825↗
- Paper Differential miRNA and Protein Expression Reveals miR-1285, Its Targets TGM2 and CDH-1, as Well as CD166 and S100A13 as… DOI 10.3390/cancers16152726↗
- Stephan A. Hahn · 2 shared papers, 2023–2024 · strength 0.38
- Paper Maintenance Therapy for Pancreatic Cancer, a New Approach Based on the Synergy between the Novel Agent GP-2250 (Misetio… DOI 10.3390/cancers16142612↗
- Paper GP-2250, a novel anticancer agent, inhibits the energy metabolism, activates AMP-Kinase and impairs the NF-kB pathway i… DOI 10.1111/jcmm.17825↗
- Hanns Möhler Abc · 1 shared paper, 2023 · strength 0.17
- Sven‐Thorsten Liffers · 1 shared paper, 2024 · strength 0.17
- Theodoros Kolokotronis · 1 shared paper, 2024 · strength 0.17
- Matthias Glanemann · 1 shared paper, 2024 · strength 0.17
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.